Fibrinogen alpha chain

Fibrinogen alpha chain is a protein that plays a crucial role in the blood coagulation process, which is essential for wound healing and stopping bleeding. It is one of the three chains (alpha, beta, and gamma) that make up the fibrinogen molecule, a soluble plasma protein produced by the liver. Fibrinogen is converted by thrombin into fibrin during blood coagulation, forming a fibrin mesh that traps blood cells to form a stable blood clot.

Structure

The fibrinogen alpha chain is encoded by the FGA gene in humans. This chain, along with the beta (FGB) and gamma (FGG) chains, forms the hexameric fibrinogen molecule through disulfide bonds. Each fibrinogen molecule is composed of two sets of these three chains, resulting in the structure (αβγ)_2. The alpha chain plays a significant role in the polymerization of fibrinogen into fibrin and in the cross-linking that provides the clot with stability.

Function

The primary function of the fibrinogen alpha chain is in the formation of the fibrin clot. Upon activation by thrombin, fibrinogen undergoes a conformational change that exposes binding sites for other fibrinogen molecules, leading to the formation of a fibrin network. The alpha chain contains specific sites that are involved in the cross-linking of fibrin strands by the enzyme factor XIII, further stabilizing the clot.

Clinical Significance

Alterations in the fibrinogen alpha chain can lead to various bleeding disorders. Congenital fibrinogen deficiencies, such as afibrinogenemia (complete lack of fibrinogen), hypofibrinogenemia (low levels of fibrinogen), and dysfibrinogenemia (functionally defective fibrinogen), are rare but can lead to significant bleeding complications or thrombotic events. These conditions can be diagnosed through blood tests that measure fibrinogen levels and function.

Genetics

The FGA gene is located on chromosome 4q31.3 and contains 10 exons. Mutations in the FGA gene can result in the aforementioned fibrinogen disorders. Genetic testing can identify mutations in individuals with suspected fibrinogen deficiencies or dysfunctions.

Treatment

Treatment for disorders related to the fibrinogen alpha chain depends on the severity and nature of the condition. For individuals with bleeding symptoms, treatment may include fibrinogen concentrate infusions to restore normal levels. In cases of dysfibrinogenemia with thrombotic risk, anticoagulant therapy may be considered.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian